RN316, a key compound for the bococizumab development program, represents a significant area of research for targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Related compounds, often referred to as https://www.targetmol.com/compound/bococizumab
Bococizumab: A Deep Dive into RN316 and Related Compounds
Internet 9 days ago bococizumab081041Web Directory Categories
Web Directory Search
New Site Listings